Using Bone Turnover Markers to Predict Changes in BMD After Alendronate Therapy in Postmenopausal Women

被引：0
|
作者：
Mcnabb, Brian [1 ]
Vittinghoff, Eric [2 ]
Schwartz, Ann [2 ]
Bauer, Douglas [2 ]
Ensrud, Kristine [3 ,4 ]
Barrett-Connor, Elizabeth [5 ]
Eastell, Richard [6 ]
Black, Dennis [2 ]
机构：
[1] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Univ Minnesota, Minneapolis, MN 55455 USA
[4] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA
[5] Univ Calif San Diego, San Diego, CA 92103 USA
[6] Univ Sheffield, Sheffield S10 2TN, S Yorkshire, England
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2014年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SU0283
引用
收藏
页码：S291 / S291
页数：1
相关论文
共 50 条
  • [41] Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis
    Mengu Sarioglu
    Cigdem Tuzun
    Zeliha Unlu
    Canan Tikiz
    Fatma Taneli
    B. Sami. Uyanik
    Rheumatology International, 2006, 26 : 195 - 200
  • [42] Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis
    Sarioglu, M
    Tuzun, C
    Unlu, Z
    Tikiz, C
    Taneli, F
    Uyanik, BS
    RHEUMATOLOGY INTERNATIONAL, 2006, 26 (03) : 195 - 200
  • [43] Early Changes in Bone Turnover Markers Predict Bone Loss After Kidney Transplantation
    Joergensen, Hanne S.
    D'Haese, Patrick
    Cavalier, Etienne
    Evenepoel, Pieter
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 19 - 20
  • [44] EFFECTS OF ORAL ALENDRONATE AND INTRANASAL SALMON-CALCITONIN ON BONE MASS AND BIOCHEMICAL MARKERS OF BONE TURNOVER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
    ADAMI, S
    PASSERI, M
    ORTOLANI, S
    BROGGINI, M
    CARRATELLI, L
    CARUSO, I
    GANDOLINI, G
    GNESSI, L
    LAURENZI, M
    LOMBARDI, A
    NORBIATO, G
    PRYORTILLOTSON, S
    REDA, C
    ROMANINI, L
    SUBRIZI, D
    WEI, L
    YATES, AJ
    BONE, 1995, 17 (04) : 383 - 390
  • [45] Direct comparison of changes in bone density and bone turnover markers in postmenopausal women with low bone mass treated with 6-monthly denosumab or weekly alendronate (Fosamax®.
    Deal, C.
    Brown, J. P.
    Recker, R.
    Prince, R.
    Kiel, D. P.
    Alvaro-Gracia, J. M.
    de Gregorio, L. H.
    Hadji, P.
    Hofbauer, L. C.
    Wang, H.
    Austin, M.
    Newmark, R.
    Libanati, C.
    Wagman, R. B.
    Martin, J. San
    Bone, H. G.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S940 - S940
  • [46] Biochemical markers of bone turnover changes effected by prolonged walking exercise in postmenopausal women
    Kimura, Y
    Yamazaki, S
    Ohki, K
    Hamada, K
    JOURNAL OF AGING AND PHYSICAL ACTIVITY, 2000, 8 (03) : 286 - 286
  • [47] Monitoring antiosteoporotic treatment of postmenopausal women using biochemical markers of bone turnover
    Kress, BC
    Mizrahi, IA
    DRUGS OF TODAY, 1999, 35 (03) : 181 - 185
  • [48] Spectroscopic markers of bone quality in alendronate-treated postmenopausal women
    Boskey, A. L.
    Spevak, L.
    Weinstein, R. S.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 (05) : 793 - 800
  • [49] Spectroscopic markers of bone quality in alendronate-treated postmenopausal women
    A. L. Boskey
    L. Spevak
    R. S. Weinstein
    Osteoporosis International, 2009, 20 : 793 - 800
  • [50] EFFECT OF VITAMIN D THERAPY ON BONE TURNOVER MARKERS IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AND OSTEOPENIA
    Tanzy, Margaret E.
    Camacho, Pauline M.
    ENDOCRINE PRACTICE, 2011, 17 (06) : 873 - 879
12345